GLNet: global-local feature network for wheat leaf disease image classification.

Addressing the issues with insufficient multi-scale feature perception and incomplete understanding of global information in traditional convolutional neural networks for image classification of wheat leaf disease, this paper proposes a global local feature network, i.e. GLNet, which adopts a unique global-local convolutional neural network architecture, realizes the comprehensive capturing of multi-scale features in an image by processing the global feature block and local feature block in parallel and integrating the information of both of them with the help of a feature fusion block.

An Emerging Toolkit of Ho Sensitized Lanthanide Nanocrystals with NIR-II Excitation and Emission for Bioimaging.

Optical imaging in the second near-infrared window (NIR-II, 1000-1700 nm) holds great promise for biomedical detection due to reduced tissue scattering and autofluorescence. However, the rational design of NIR-II probes with superior excitation wavelengths to balance the effects of tissue scattering and water absorption remains a great challenge. To address this issue, here we developed a series of Ho-sensitized lanthanide (Ln) nanocrystals (NaYF: Ho, Ln@NaYF) excited at 1143 nm, featuring tunable emissions ranging from 1000 to 2200 nm for bioimaging.

Digital Rehabilitation Program for Breast Cancer Survivors on Adjuvant Hormonal Therapy: A Feasibility Study.

: Breast cancer survivors often face physical and psychological challenges, including weight gain, metabolic syndrome, and reduced quality of life. To address these concerns, a mobile app-based rehabilitation program called "THRIVE" was developed to improve physical activity, medication adherence, and health-related quality of life (HRQoL) in this population. : This prospective, single-arm study assessed the feasibility and effectiveness of the "THRIVE" app among breast cancer survivors undergoing hormonal therapy.

Development of a Long-Acting Follicle-Stimulating Hormone Using Serum Albumin Fab-Associated Technology for Female Infertility.

Background: Recombinant human follicle-stimulating hormone (rhFSH) is commonly used to treat female infertility, but its short half-life necessitates multiple doses. Even corifollitropin alfa, with an extended half-life, requires supplementary injections of rhFSH after 7 days. This study aimed to develop and evaluate a long-acting follicle-stimulating hormone (FSH) formulation using anti-serum albumin Fab-associated (SAFA) technology to avoid additional injections and enhance ovarian function.